Stephen D Smith
Overview
Explore the profile of Stephen D Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
1927
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
Rivas A, Smith S, Basiladze V, Chaligava T, Malania L, Burjanadze I, et al.
Front Vet Sci
. 2024 Jan;
10:1270505.
PMID: 38179332
Introduction: Control of zoonosis can benefit from geo-referenced procedures. Focusing on brucellosis, here the ability of two methods to distinguish disease dissemination patterns and promote cost-effective interventions was compared. Method:...
13.
Budde L, Olszewski A, Assouline S, Lossos I, Diefenbach C, Kamdar M, et al.
Nat Med
. 2023 Dec;
30(1):229-239.
PMID: 38072960
Relapsed/refractory aggressive large B cell lymphoma (LBCL) remains an area of unmet need. Here we report the primary analysis of a phase 1b/2 trial of outpatient mosunetuzumab (a CD20xCD3 T-cell-engaging...
14.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, et al.
J Natl Compr Canc Netw
. 2023 Nov;
21(11):1118-1131.
PMID: 37935098
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the...
15.
Ho C, Gopal A, Till B, Shadman M, Lynch R, Cowan A, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Nov;
24(2):e33-e39.e1.
PMID: 37926672
Background: While generally ineffective in relapsed diffuse large B cell lymphoma (DLBCL), immune checkpoint inhibitors (ICIs) may hold greater promise in untreated, immunocompetent patients. We previously reported safety and early...
16.
17.
Le Gouill S, Dlugosz-Danecka M, Rule S, Zinzani P, Goy A, Smith S, et al.
Haematologica
. 2023 Jul;
109(1):343-350.
PMID: 37470152
No abstract available.
18.
Whiteaker J, Zhao L, Schoenherr R, Huang D, Lundeen R, Voytovich U, et al.
Front Oncol
. 2023 May;
13:1168710.
PMID: 37205196
Introduction: Immunotherapy is an effective treatment for a subset of cancer patients, and expanding the benefits of immunotherapy to all cancer patients will require predictive biomarkers of response and immune-related...
19.
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, et al.
Blood Adv
. 2023 May;
7(21):6381-6394.
PMID: 37171397
In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)-a rare category defined by high-grade morphologic features and...
20.
McQuarrie A, Smith S, Jakobson L
Front Psychol
. 2023 May;
14:1072783.
PMID: 37151350
Introduction: Empathy-the ability to identify and share another person's emotional state-is an important socio-emotional process arising, in part, from emotional contagion. In the current study, we assessed unique variance in...